Skip to content
Herceptin(trastuzumab)
Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Phesgo, Trazimera (trastuzumab) is an antibody pharmaceutical. Trastuzumab was first approved as Herceptin on 1998-09-25. It is used to treat breast neoplasms and gastrointestinal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms and stomach neoplasms. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
Combinations
Herceptin hylecta, Phesgo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Hyaluronidase
+
Pertuzumab
+
Trastuzumab
Tradename
Proper name
Company
Number
Date
Products
Phesgopertuzumab, trastuzumab, and hyaluronidase-zzxfGenentechN-761170 RX2020-06-29
2 products
Trastuzumab
Tradename
Proper name
Company
Number
Date
Products
HerceptintrastuzumabGenentechN-103792 RX2017-02-10
1 products
Show 1 discontinued
Hyaluronidase
+
Trastuzumab
Tradename
Proper name
Company
Number
Date
Products
Herceptin Hylectatrastuzumab and hyaluronidase-oyskGenentechN-761106 RX2019-02-28
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
herceptinBiologic Licensing Application2020-10-19
herzumaBiologic Licensing Application2020-03-19
kadcylaBiologic Licensing Application2023-06-06
kanjintiBiologic Licensing Application2019-10-25
ogivriBiologic Licensing Application2021-02-08
ontruzant ontruzant Biologic Licensing Application2023-01-31
phesgoBiologic Licensing Application2020-06-29
trazimeraBiologic Licensing Application2021-03-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
breast neoplasmsEFO_0003869D001943C50
gastrointestinal neoplasmsD005770C26.9
Agency Specific
FDA
EMA
Expiration
Code
trastuzumab, Herceptin, Genentech, Inc.
2117-10-20Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01F: Monoclonal antibodies and antibody drug conjugates
L01FD: Her2 (human epidermal growth factor receptor 2) inhibitors
L01FD01: Trastuzumab
L01FD03: Trastuzumab emtansine
L01FD04: Trastuzumab deruxtecan
L01FD05: Trastuzumab duocarmazine
L01X: Other antineoplastic agents in atc
L01XY: Combinations of antineoplastic agents
L01XY02: Pertuzumab and trastuzumab
HCPCS
Code
Description
J9316
Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg
J9354
Injection, ado-trastuzumab emtansine, 1 mg
J9355
Injection, trastuzumab, excludes biosimilar, 10 mg
J9356
Injection, trastuzumab, 10 mg and hyaluronidase-oysk
J9358
Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
Q5112
Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
Q5113
Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
Q5114
Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
Q5116
Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
Q5117
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
Clinical
Clinical Trials
1000 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501693951381246683
NeoplasmsD009369C80343251873
Stomach neoplasmsD013274EFO_0003897C161538111561
Male breast neoplasmsD0185679112120
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228910141123
Colorectal neoplasmsD0151797161121
AdenocarcinomaD0002303172220
Brain neoplasmsD001932EFO_0003833C71713117
Triple negative breast neoplasmsD064726811116
Esophageal neoplasmsD004938C15710216
Neoplasm metastasisD009362EFO_000970848111
Inflammatory breast neoplasmsD0589223439
Invasive hydatidiform moleD002820D39.23518
Biliary tract neoplasmsD001661C24.9516
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C258814
Urinary bladder neoplasmsD001749C674911
Endometrial neoplasmsD016889EFO_00042308510
Ovarian neoplasmsD010051EFO_0003893C5655110
Lung neoplasmsD008175C34.9048110
Prostatic neoplasmsD011471C612417
Multiple myelomaD009101C90.0256
Salivary gland neoplasmsD012468EFO_0003826D11246
Rectal neoplasmsD012004156
Urologic neoplasmsD014571C64-C68156
Show 44 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1414
Hodgkin diseaseD006689C8122
Ovarian epithelial carcinomaD00007721622
Myelodysplastic syndromesD009190D4611
Myeloid leukemia acuteD015470C92.011
Primary myelofibrosisD055728D47.411
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
B-cell chronic lymphocytic leukemiaD015451C91.111
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034011
Myelomonocytic leukemia chronicD015477C93.111
Show 28 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObservationD01937011
FatigueD005221HP_0012378R53.8311
PregnancyD011247EFO_0002950Z33.111
Second primary neoplasmsD01660911
RecurrenceD01200811
Intraductal carcinoma noninfiltratingD002285D05.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRASTUZUMAB
INNtrastuzumab
Description
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)TRASTUZUMAB
Structure (InChI/SMILES or Protein Sequence)
>5U6A:A|Light Chain DIQMTQSPILLSASVGDRVTITCRASQDVNTAVAWYQQRTNGSPRLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQP EDEADYYCQQHYTTPPTFGAGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >5U6A:B|Heavy Chain EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQSPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAIYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
Identifiers
PDB4HJG, 4HKZ, 4IOI, 5U3D, 5U5F, 5U5M, 5U6A, 5XHF, 5XHG, 6B9Y, 6B9Z, 6BAE, 6BAH, 6BGT, 6BHZ, 6BI0, 6BI2, 6OGE, 7MN8, 7PKL
CAS-ID180288-69-1
RxCUI224905
ChEMBL IDCHEMBL1201585
ChEBI ID
PubChem CID
DrugBankDB00072
UNII IDP188ANX8CK (ChemIDplus, GSRS)
Target
Agency Approved
ERBB2
ERBB2
Organism
Homo sapiens
Gene name
ERBB2
Gene synonyms
HER2, MLN19, NEU, NGL
NCBI Gene ID
Protein name
receptor tyrosine-protein kinase erbB-2
Protein synonyms
c-erb B2/neu protein, CD340, herstatin, human epidermal growth factor receptor 2, Metastatic lymph node gene 19 protein, MLN 19, neuro/glioblastoma derived oncogene homolog, neuroblastoma/glioblastoma derived oncogene homolog, p185erbB2, Proto-oncogene c-ErbB-2, Proto-oncogene Neu, Tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
Uniprot ID
Mouse ortholog
Erbb2 (13866)
receptor tyrosine-protein kinase erbB-2 (Q6ZPE0)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Ontruzant - Organon
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Phesgo - Roche
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Herceptin - Halozyme Therapeutics
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Herceptin - Roche
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Trazimera - Pfizer
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 52,928 documents
View more details
Safety
Black-box Warning
Black-box warning for: Herceptin, Herzuma, Kadcyla, Kanjinti, Ogivri, Ontruzant ontruzant , Phesgo, Trazimera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15,170 adverse events reported
View more details